• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Several Lots of Human Growth Hormone Have Been Recalled


An FDA inspection of compound pharmacy Innoveix Pharmaceuticals indicated these lots may not be sterile.

Innoveix Pharmaceuticals, a compounding pharmacy in Addison, Tex., is voluntarily recalling several lots of compounded drug products. The products are being recalled due to a lack of assurance of sterility. The issues where discovered during a routine inspection by the FDA.

The affected products are injectable sermorelin/ipamorelin 3mg and injectable AOD-9604 3mg. Sermorelin and ipamorelin are human growth hormone secretagogues (GHSs), which are compounds that increase growth hormone release. AOD is a synthetic peptide thought to have potential for weight loss.

To date, Innoveix Pharmaceuticals has not received any reports of adverse events related to this recall.

Sermorelin / Ipamorelin 3mg

  • Lot# SIP210; Exp: 12/15/2021
  • Lot# SIP215; Exp: 01/14/2022
  • Lot# SIP220; Exp: 01/23/2022

AOD-9604 3mg

  • Lot# AOD205; Exp: 11/09/2021
  • Lot# AOD210; Exp: 11/18/2021
  • Lot# AOD 215; Exp: 12/15/2021
  • Lot# AOD202; Exp: 11/09/2021
Related Content
© 2024 MJH Life Sciences

All rights reserved.